ArticleAmerican journal of nuclear medicine and molecular imaging2023
Comparison of PSMA-based
Article in American journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Prostate-specific membrane antigen PET versus [Frontiers in medicine · 2024Pooled it
- Effect of bone marrow disease on hematologic toxicity and response to [European journal of nuclear medicine and molecular imaging · 2026Article
- A seven-variable clinical prediction model for bone metastasis at initial diagnosis of prostate cancer.American journal of cancer research · 2026Article
- Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.Skeletal radiology · 2025Article
- Noninvasive PET imaging of tumor PD-L1 expression withAmerican journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While Tc-99m MDP bone scan (BS) remains the conventional standard for detection of bone metastasis in prostate cancer, newly FDA-approved imaging with PSMA-based
Indexed as
Identifiers
36923600PMC10009469W4327677482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.